ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Management Failure

<< Previous

Bullboard Posts

Next >>

Comment by M101on Sep 17, 2020 5:40pm

157 Views

Post# 31578462

RE:RE:Management Failure

Agree that management shuffle may not help as I believe it will be the technology which sells itself, but it's just not ready yet. Of course I would never expect to hear this from Gene or Elliot.
What would help though is management taking a serious part of their package in options instead of cash. This would help not just with cash flow but with the market's perception of inherent technological risk and questionable financial management.

<< Previous

Bullboard Posts

Next >>

Three mispriced stocks exposed to major market tailwinds